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DObjective: Efficacy of the maze procedure for atrial fibrillation associated with advanced mitral disease not ame-
nable to repair has not been determined. This study investigated whether type of mitral surgery affects maze out-
come.
Methods: From January 1999 to January 2007, a total of 435 patients underwent the maze procedure and con-
comitant mitral operation. Of these, 226 underwent mitral repair and 209 underwent mitral replacement.
Results:Median follow-up was 40.6 months (0.4–111.3 months), with 25 deaths and 6 strokes. Nineteen patients
did not regain normal sinus rhythm. There were no significant intergroup differences in survival, stroke incidence,
or sinus rhythm restoration rate. Among 427 early survivors, 64 had late atrial fibrillation recurrence. Five-year
atrial fibrillation–free rates were 80.9% 3.7% in the repair group and 77.3% 4.1% in the replacement group
(P ¼ .099). By multivariate analysis, age at surgery older than 60 years (P ¼ .045), fine atrial fibrillation wave
pattern (P ¼ .033), and preoperative left atrial dimension greater than 60 mm (P ¼ .019) were independent risk
factors for atrial fibrillation recurrence, whereas type of mitral surgery was not (P ¼ .573). Although transmitral
A-wave prevalence did not differ significantly between groups beyond the early postoperative period, A-wave
velocity was faster in the repair group through the entire postoperative period (P< .001).
Conclusions:Maze outcomes were acceptable regardless of type of mitral surgery. Late atrial fibrillation recur-
rence was mainly affected by age, unfavorable electrocardiographic characteristics of atrial fibrillation, and larger
preoperative left atrial size. (J Thorac Cardiovasc Surg 2010;139:111-7)Atrial fibrillation (AF) is observed in 40% to 60% of
patients who require mitral valve (MV) surgery, with the
treatment of choice being the maze operation in association
with MV repair when repair is technically feasible.1,2 The
efficacy of the maze operation in patients who require
MV replacement, however, is still unclear,3,4 in that (1)
anticoagulation after valve replacement may be sufficient
to prevent cerebrovascular accidents (CVAs), even without
the restoration of normal sinus rhythm, and (2) the outcome
of the maze operation may be less than optimal in patients
with advanced MV pathology that is not reparable. Because
MV replacement is indicated only for patients with difficult
to correct, advanced MV pathology, such as rheumatic
mitral disease, such patients probably have more advanced
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The Journal of Thoracic and Cathat these patients may respond poorly to efforts to eliminate
AF.5
In a study evaluating the outcomes of the maze procedure
combined with a MV operation,6 MV replacement (rather
than repair) was found to be a significant risk factor for op-
erative mortality. That study, however, focused mainly on
immediate postoperative outcomes and did not consider
long-term cardiac rhythm and thromboembolic complica-
tions.
Because recurrence of AF after the maze procedure may
not be directly related to the MV procedure per se, it may
be important to delineate which patients can benefit from
the maze operation even if the MV is to be replaced. We
therefore investigated clinical results of the maze procedure
combined with a MV procedure and analyzed whether the
type of MV operation chosen might affect the outcome of
the maze operation.MATERIALS AND METHODS
Patients
From January 1999 to January 2007, a total of 435 patients with MV dis-
ease underwent surgery for persistent or paroxysmal AF. The maze proce-
dure and the MV operation were performed concomitantly, with or
without other cardiac procedures. Of these 435 patients, 226 underwent
MV repair (repair group) and 209 underwent MV replacement (replacement
group), depending on the severity of valve pathology. Preoperative transe-
sophageal echocardiography was routinely performed to evaluate MVrdiovascular Surgery c Volume 139, Number 1 111
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LA ¼ left atrial
MV ¼ mitral valvemorphology. Rheumatic etiology of mitral valvulopathy was suggested by
medical history, echocardiographic assessment, and intra-operative findings
of valve morphology. In an effort to prevent postoperative sick sinus syn-
drome, preoperative coronary angiography was routinely performed in all
patients to verify the origin and course of the sinus nodal artery. Sinus nodal
arteries originated from the right coronary system in 205 patients and from
the left coronary system in 152 patients. During creation of maze lesions (ei-
ther incisions or ablation), these arteries were strictly preserved. This study
was approved by the institutional review board.
Surgical Techniques
Maze procedures were performed with a modified Cox maze III tech-
nique, the details of which have been described previously.7 In brief, the
technical modification centers around preservation of the LA function after
maze operation: (1) LA tissue incorporation on pulmonary vein isolation
procedure was minimized by tightly encircling the pulmonary vein orifices,
(2) cut and sew technique was replaced with ablation with either cryother-
mia (n¼ 333) or microwave (n¼ 102), and (3) LA size was reduced by gen-
erous resection of redundant atrial tissue off the posterior LAwall parallel to
the posterior mitral annulus. Cryoablation was applied at60C with a 15-
angled, 30- or 70-mm long freeze tip with a diameter of 9 mm (Frigitronics
Cardiac Cryosurgical System 200; Frigitronics, Inc, Coopersurgical, Shel-
ton, Conn). The probe was usually applied for 2 minutes.Microwave energy
was applied endocardially with FLEX 4 microwave ablation probes (Afx
Inc, Fremont, Calif). The energy level used was 65 W, and duration of ab-
lation was 1 to 2 minutes, depending on the myocardial thickness. The de-
gree of LA wall resection was determined by preoperative LA size, with
a target postoperative LA size greater than 50 mm. Ablation of the right
atrial cavotricuspid isthmus was performed to prevent postoperative atrial
flutter. MV replacement was performed in a chordae-sparing manner. One
hundred seventy-five patients in the replacement group (83.7%) received
mechanical valves.
Postoperative Follow-up
Any symptoms suggestive of neurologic deficit were evaluated by neu-
rologists with adequate imaging studies. Bleeding complication from anti-
coagulation therapy was defined as any significant bleeding necessitating
transfusion, intervention, or readmission.
Postoperatively, inpatient rhythms were monitored daily with standard
12-channel surface electrocardiography. Patients were routinely evaluated
with 24-hour Holter monitoring before hospital discharge. Follow-up elec-
trocardiography was routinely performed at 3- to 6-month intervals during
the first 2 years and every year thereafter. Any symptoms suggestive of ar-
rhythmia were assessed by 24-hour Holter monitoring during follow-up.
Recurrences or events of AF during the initial postablation blanking period
of 3 months were considered early events. A failure of the maze procedure
was defined as any recurrent AF, atrial tachycardia, or atrial flutter at least 3
months after stopping amiodarone beyond the initial blanking period. The
end point used was freedom from AF without antiarrhythmic agent, the
time before first AF events were presented.
Transthoracic echocardiographic evaluations were performed at 3 and 6
months and every year thereafter. Two-dimensional echocardiography and
Doppler color flow imaging were performed in all cases with a Hewlett-
Packard Sonos 2500 or 5500 imaging system equipped with a 2.5-MHzJournal of Thoracic and Cardiovascular Surgtransducer (Hewlett-Packard, Andover, Mass). Patients were monitored
for the presence of transmitral A waves and the magnitude of peak A-
wave velocity. The prevalence of transmitral A-wave as a percentage is de-
rived from the number of patients with the presence of transmitral A wave
divided by the number of patients with normal sinus rhythm multiplied by
100% at each postoperative time point.
All data were collected prospectively and stored for later assessment in
a specially designed and controlled database.
Postoperative Management
Postoperative AF, atrial flutter, atrial tachycardia, frequent atrial prema-
ture beats, and recurrent atrial tachyarrhythmia were treated with amiodar-
one, which was commenced at 1200 mg/d and tapered according to rhythm
status. Rapid ventricular rate despite amiodarone therapy was controlled by
b-blockers or calcium-channel blockers. Patients who underwent valve re-
pair or bioprosthesis insertion (n ¼ 34) routinely had anticoagulation with
warfarin for 3 to 6 months postoperatively with target international normal-
ized ratio of 1.5 to 2.5 at the discretion of the attending surgeon. The main-
tenance of anticoagulation therapy thereafter was determined according to
individual risk factors of thromboembolism and cardiac rhythm status.
Any patient who showed AF after operation received anticoagulation ther-
apy, which was continued unless sinus rhythm was restored. For patients
with mechanical valve implantation, an international normalized ratio of
2.0 to 3.0 was the aim, regardless of cardiac rhythm status.
Statistics
Data are presented as frequency,meanSD, ormedianwith range.Com-
parisons of patient characteristics between the groups (replacement vs repair)
were performed with c2 tests for categoric variables and Student t tests for
continuous variables. Kaplan–Meier curves were used to delineate time-re-
lated recurrence of AF. Stratified survival curves (freedom from AF) were
plotted to explore unadjusted differences for variables of interest (log-rank
test). For multivariate analysis, Cox proportional hazards model was fitted
with time to AF recurrence, adjusting for potential risk factors. For the inter-
group comparisons of transmitral A-wave prevalence and velocity at each
postoperative time point, c2 and Student t tests, respectively, were used.
Postoperative changes in transmitral peak A-wave velocity were investi-
gated with repeatedmeasures analysis of variance. The SPSS software pack-
age (version 12; SPSS, Inc, Chicago, Ill) was used for statistical analysis.RESULTS
Perioperative Characteristics
Clinical follow-up was complete for all patients at a me-
dian of 40.6months (0.4–111.3months). Cardiac rhythm fol-
low-up for 12 months was possible in 400 patients (91.9%).
Median age at operationwas 52 years (18–80 years), and 264
patients (60.6%) were female. There were no significant
between-group differences in mean age at surgery, sex distri-
bution, LA size, left ventricular ejection fraction, and cardio-
thoracic ratio (Table 1). Reoperation, concomitant aortic
valve procedure, longer history of AF, and rheumatic
origin of mitral valvulopathy were more frequently observed
in the replacement group than in the repair group.Operative Outcomes
There were 8 early and 17 late deaths (Table 2). Nineteen
patients (4.3%) did not regain normal sinus rhythm. LA size
decreased from 60.2 10.0 mm to 47.7 7.1 mm as a result
of the surgery (P<.001). One hundred six patients had earlyery c January 2010
TABLE 1. Preoperative patient characteristics
Repair Replacement P value
Patients (No.) 226 209
Age (y, mean  SD) 50.3  13.8 51.1  11.5 .529
Male/female ratio 97:129 74:135 .109
Cardiothoracic ratio (%,
mean  SD)
59.8  8.2 59.3  10.3 .554
Reoperation 8 (4.4%) 18 (8.6%) .026
Atrial fibrillation profile
Duration (y, mean  SD) 4.5  5.0 6.8  7.5 <.001
Coarse/fine ratio 122:100 115:88 .725
Type (No.) .345
Paroxysmal 28 (12.4%) 17 (8.1%)
Persistent 60 (26.5%) 59 (28.2%)
Longstanding persistent
(>1 y)
138 (61.1%) 133 (63.6%)
Echocardiography
Left atrial dimension (mm,
mean  SD)
60.1  10.4 60.2  9.5 .949
Rheumatic mitral disease 102 (45.1%) 182 (87.1%) <.001
Left ventricular ejection
fraction (%, mean  SD)
55.2  10.7 55.0  8.8 .806
TABLE 3. Operative profiles and outcomes
Repair Replacement P value
Operative profile
Aortic crossclamp time (min,
mean  SD)
59.8  8.2 59.3  10.3 .309
Cardiopulmonary bypass time
(min, mean  SD)
114.7  30.2 116.6  33.8 .542
Maze energy source (no.) .107
Cryothermia 166 167
Microwave ablation 60 42
Concomitant procedures (no.)
AVR or AVP 23 49 <.001
CABG 12 10 .803
AVR or AVP plus CABG 5 3 .547
Atrial, ventricular, or
atrioventricular septal
defect closure
12 5 .117
Aortic surgery 4 0 .830
Others 4 5 .649
Operative outcome
Permanent pacemaker
insertion (no.)
3 (1.3%) 7 (3.3%) .160
Early mortality (no.) 4 (1.8%) 4 (1.9%) .911
Cerebrovascular accident (no.) 3 (1.3%) 3 (1. 4%) >.999
Multiple embolic 2 3
Right middle cerebral
artery occlusion
1
AVR, Aortic valve replacement; AVP, aortic valve repair; CABG, coronary artery
bypass grafting.
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DAF events (51 in the repair group and 55 in the replacement
group, P ¼ .399). Of 427 early survivors, 64 had late AF re-
currence (15.0%). Normal sinus rhythm was present at last
follow-up in 82.7% of patients. The overall AF-free rates
were 86.2%  1.9% at 3 years, 78.3%  2.8% at 5 years,
and 70.2%  4.4% at 7 years. There were 6 late CVAs (no
early CVAs), with 1 death and 5 permanent neurologic im-
pairments (Table 3). All 6 patients with CVAwere receiving
anticoagulation therapy when CVA occurred. Only 1 patient
in the repair group was in AF when CVA occurred; the re-
maining 5 were in normal sinus rhythm.
There were no significant between-group differences in
CVA incidence, mortality, and rates of permanent pace-
maker implantation (Table 3). There were no intergroup dif-
ferences in sinus conversion rate, mean date of sinus
conversion, and the last follow-up electrocardiographic
rhythm (Table 4). The 5-year freedoms from AF without an-
tiarrhythmic agent were 80.9%  3.7% in the repair groupTABLE 2. Details of mortality
Repair Replacement P value
Early mortality (n ¼ 8) 4 4
Cardiac death 4 2 >.999
Gastrointestinal bleeding 1
Left ventricular rupture 1
Late mortality (n ¼ 17) 10 7
Cardiac death 4 2 .563
Malignancy 2
Respiratory failure 2
Bacterial meningitis 1
Cerebrovascular accident 1
Unknown 3 2
The Journal of Thoracic and Caand 77.3%  4.1% in the replacement group (P ¼ .099;
Figure 1).Assessment of Risk Factors for Late AF Recurrence
Univariate analyses to determine factors associated with
late AF recurrence without antiarrhythmic agents revealed
that older patient age, longer preoperative AF duration,
fine AF wave pattern, and greater LA size were significant
factors. The influences of rheumatic etiology of mitral val-
vulopathy, MV operation type and concomitant perfor-
mance of coronary artery bypass grafting on AF
recurrence were statistically marginal. Cox multivariateTABLE 4. Postoperative cardiac rhythm
Repair Replacement P value
Sinus conversion (no.) 208 (92.0%) 196 (93.8%) .585
Sinus conversion date
(d, mean  SD)
1.2  2.5 1.0  6.7 .394
Recent follow up rhythm
(no.)
.592
Normal sinus rhythm 188 172
Atrial fibrillation or
flutter
31 25
Junctional rhythm 4 5
Pacemaker rhythm 3 7
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FIGURE 1. Freedoms from atrial fibrillation (AF) without antiarrhythmic
agents. Three- and 5-year atrial fibrillation–free rates, respectively, were
88.7%  2.4% and 80.9%  3.7% in repair (MVP) group and 83.2% 
3.1% and 77.3%  4.1% in replacement (MVR) group. AMD, Amiodar-
one.
TABLE 5. Univariate and multivariate analyses of risk factors
associated with late atrial fibrillation recurrence without
antiarrhythmic medication
Multivariate analysis
Univariate
P value
Hazard
ratio 95% CI P value
Preoperative factors
Age ($60 y) .023 1.81 1.01–3.22 .045
AF duration ($5 y) .004 1.45 0.85–2.47 .174
Fine (<1 mm) AF wave
pattern (vs coarsewave)
.006 1.74 1.04–2.91 .033
AF type
Paroxysmal Reference
Persistent .453
Longstanding
persistent
.123
Left atrial size ($60 mm) .009 1.92 1.11–3.33 .019
Left ventricular ejection
fraction (<50%)
.283
Rheumatic mitral disease
(vs nonrheumatic)
.067 1.57 0.79–3.12 .198
Previous cardiac surgery .901
Operative factors
Mitral operation type
(replacement vs repair)
.099 1.17 0.67–2.02 .573
Microwave ablation (vs
cryoablation)
.103
Concomitant coronary
artery bypass grafting
.348
Concomitant aortic valve
surgery
.135 1.45 0.79–2.82 .209
Not all factors were entered into the multivariate model. CI, Confidence interval;
AF, atrial fibrillation.
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firmed that older patient age, fine AF wave pattern, and
greater LA size were independent risk factors for late AF re-
currence. After adjustment, mitral surgery type did not cor-
relate with AF recurrence (Table 5).
Postoperative Antiarrhythmic Medication and
Anticoagulation Therapy
Seventy-three patients in the repair group and 80 patients
in the replacement group were given amiodarone within 3
months after operation (P ¼ .228). The rate of amiodarone
medication in the early postoperative period (3 months)
was significantly greater in patients with early AF events
than in those without early events (81/316 in no early events
group vs 71/106 in early events group, P< .001).
Beyond 3 months after operation, 32 patients in the repair
group and 27 patients in the replacement group received
amiodarone medication (P ¼ .706). The rate of amiodarone
medication beyond the early postoperative period (>3
months) was also significantly greater among patients with
late AF recurrence than among those without late AF recur-
rence (18/317 in no AF recurrence group vs 38/64 in AF re-
currence group, P<.001). Three hundred seventeen patients
who were free of late AF recurrence eventually had normal
sinus rhythm after discontinuation of amiodarone.
After 6 postoperative months, 19.9% of patients in the re-
pair group (n ¼ 45) and 91.8% in the replacement group (n
¼ 192) received warfarin medication (P< .001). In the re-
pair group, the indications for long-term anticoagulation
were late AF recurrence in 24 cases and other risk factors
of thromboembolism in 21. In the replacement group,
100% of patients with mechanical valves and 50% with tis-
sue valves (n¼ 17) received long-term anticoagulation ther-114 The Journal of Thoracic and Cardiovascular Surgapy. There were 34 patients who had bleeding complications
during follow-up. These patients comprised 3.5% of the re-
pair group (n¼ 8) and 12.4% of the replacement group (n¼
26, P ¼ .001).Assessment for Transmitral AWaves
In intergroup comparisons of transmitral A-wave preva-
lence, the only differences were found at 1 month, with
higher A-wave prevalence at both time points observed in
the repair group (Figure 2). Beyond the immediate postoper-
ative period, transmitral A-wave prevalence reached 80% to
90% and was maintained for as long as 6 years.
Transmitral peak A-wave velocity was unchanged with
time in both groups (P ¼ .146, repeated measure analysis
of variance; Figure 3). In intergroup comparisons, A-wave
velocity was significantly faster in the repair group through
the entire postoperative period.DISCUSSION
We found that the outcomes of the maze procedure were
comparable in the replacement and repair groups in terms ofery c January 2010
FIGURE 2. Transmitral A-wave prevalence plots. In intergroup compari-
sons, difference was only found at 1 month, with higher A-wave prevalence
observed in repair (MVP) group than in replacement (MVR) group. Beyond
early postoperative period, A-wave prevalence was maintained at 80% to
90% as long as 6 years without intergroup differences.
FIGURE 3. Transmitral peak A-wave velocity graphs. Repeated measures
analysis of variance revealed velocity to be unchanged with time in both
groups (P ¼ .146). In intergroup comparisons, A-wave velocity was signif-
icantly faster in repair (MVP) group than in replacement (MVR) group
through entire postoperative period.
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Doperative morbidity, overall survival, and rate of postopera-
tive CVA. In contrast to a previously reported study,6 higher
operative mortality was not observed in the replacement
group. Although Kaplan–Meier analysis suggested a poorer
result in the replacement group in terms of late AF recur-
rence with a borderline significance, multivariate analysis
revealed that older patient age, fine AF wave pattern, and
greater LA size were independent risk factors for postoper-
ative AF recurrence but that the type of MV surgery was not.
To evaluate the benefits of the maze procedure in patients
with MV disease, several groups have compared the out-
comes of the combined procedure with those of isolated
MV operation.4,8-11 A prospective trial randomly assigned
20 patients to undergo MV replacement alone (n ¼ 5) or
in combination with a maze operation (n¼ 15)8 and revealed
that the patients who underwent the maze operation accom-
panied by MV replacement had much higher rate of sinus
rhythm restoration and better functional performance on
postoperative exercise tests. Another study compared the
outcomes of patients with AF who underwent either MV re-
placement alone, MV repair plus the maze operation, or MV
replacement plus the maze operation.4 Multivariate analyses
showed that omission of the maze procedure and longer du-
ration of AF were risk factors for postoperative AF recur-
rence, with omission of the maze procedure being the only
significant risk factor for late stroke. Generally, the rate of
major systemic embolism is 2% to 3% per year after me-
chanical valve replacement, even when anticoagulation
treatment is used.12-14 In our study, we found that the inci-
dence of late postoperative CVA remained low even in the
replacement group, similar to that in the repair group. This
finding is suggestive of an additional protective effect
against CVA by restoration of sinus rhythm after the maze
operation in patients with MV replacement. Similar findingsThe Journal of Thoracic and Cahave been observed, in that CVA risk remained high in pa-
tients with MV replacement who were receiving anticoagu-
lation and that this risk was reduced when sinus rhythm was
restored.3,4 The lack of significant intergroup difference in
CVA incidence might also, however, be explained by the
low incidence of postoperative CVA itself (n¼ 6). Observa-
tion on a larger patient population with a longer follow-up
duration might offer more complete data for more discrimi-
nating analysis of CVA incidence.
Older patient age, longer preoperativeAFduration, fineAF
wave pattern, and increased LA size have been shown to be
risk factors for AF recurrence after the maze procedure.15-17
In our study, multivariate analyses revealed that older patient
age, fine AFwave pattern, and greater LA size were indepen-
dent risk factors for postoperative AF recurrence. The finding
that preoperative LA size affected maze outcome is contrary
to our previous report, in which patients with preoperative
giant LA size (>60 mm) had outcomes comparable to those
of patients with nongiant LA size in terms of postoperative
sinus conversion rates and atrial contractility in the early
and late postoperative period.18 The follow-up period of the
previous study, however, was limited to only 6 postoperative
months. Because this study clearly delineates an association
between the LA size andAF recurrence in a long-term clinical
scenario, the results from the previous report can not be
generalized as a long-term maze outcome.
In this study, AF duration was not found to be an indepen-
dent factor for AF recurrence. This finding may stem from
the limitation in calculating the AF duration, which was
based on patient memory in the case of those with symptoms
(palpitation) or on the date of first recorded AF episode in the
case of those without symptoms. This manner of calculation
does not seem to reflect the exact duration of AF. On the
other hand, the low amplitude of the AF wave indicatesrdiovascular Surgery c Volume 139, Number 1 115
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the atrial electric motive force decreases as a result of atrial
dilatation progression,19 loss of atrial contractile compo-
nents replaced with fibrosis,20,21 and degeneration of the
atrial myocardium. In determining the chronic nature of
AF, evaluation the amplitude of AF wave is thought to be
more reliable and objective than calculating AF duration,
which mainly depends on patient memory.
The outcomes of the maze procedure have been reported
to be poorer in patients with rheumatic mitral disease, sug-
gesting that this procedure should be reconsidered in such
cases.5 In contrast, another study indicated that rheumatic
MV disease itself was not related to the lower success rate
of the maze procedure, as assessed by sinus conversion
and restoration of atrial transport function,22 findings in
agreement with those shown in this study. According to
our multivariate analysis, the presence of rheumatic dis-
ease did not affect AF recurrence after the maze operation
(P ¼ .116).
Assessment of atrial transport function is regarded as an
important part of the analysis of maze outcomes. The impor-
tance of atrial contractility in patients with restored sinus
rhythm has been a subject of controversy, however, in that
restoration of atrial transport function may not contribute
to increased cardiac output or decreased thromboembolic
complications. A study that involved cardiopulmonary exer-
cise testing before and after the maze procedure suggested
that improvement in exercise capacity may not be caused
by restored sinus rhythm and atrial contraction but may be
related to the reduction in LA size and improvement in he-
modynamic variables achieved by the surgery itself.23 In
a recently reported study, however, cardiac magnetic reso-
nance imaging evaluation for patients who had sinus rhythm
following maze procedure revealed that patients with atrial
contraction had better LA booster pump and reservoir func-
tion than did those without atrial contraction.24 The latter
report strongly suggests better cardiac performances in
patients with both sinus rhythm and atrial contraction after
the maze procedure. In our series, the modification of the
maze procedure was intended to improve the LA transport
function under the assumption that restoration of atrial trans-
port function plays an important role in overall outcome.
Furthermore, patients with sinus rhythm but without
effective atrial contraction routinely received anticoagula-
tion in our practice to prevent potential thromboembolic
complications.
In this study, A-wave prevalence increased from 58% to
73% the in early postoperative period (1 month) to 80% to
90% thereafter and was maintained as late as 6 years. In in-
tergroup comparison, the difference in A-wave prevalence
was observed only at 1 postoperative month, with a higher
A-wave prevalence in the repair group. Restoration of both
sinus rhythm and atrial contractility is apparently different,
and the rate of restoring atrial contraction varies from116 The Journal of Thoracic and Cardiovascular Surg21% to 95%, with factors affecting restoration of atrial con-
traction after the maze procedure known to be AF duration,
LA diameter, and the presence of prosthetic valve failure.25
MV operation type was greatly associated with the postoper-
ative A-wave velocity in this study, which was less favorable
in the replacement group than in the repair group. This find-
ing is thought to be attributable to the differences in preop-
erative conditions, which were poorer in the replacement
group, with rheumatic mitral valvulopathy and reoperation
more frequently observed in the replacement group than in
the repair group. These adverse conditions may have re-
sulted in degenerative changes of atrial tissue characterized
by loss of atrial muscle and atrial fibrosis and thus decreased
contractility of atria. Clinical implications of the differences
in A-wave velocity and the effect of each factor on it should
be investigated in another study.LIMITATIONS
This study was retrospective in nature and was not ran-
domized. We have not determined whether a successful
maze procedure can reduce the risk of thromboembolism.
Although we speculated that AF recurrence increases the
risk of CVA, any correlation between these variables was
not provable in this study because of the low incidence of
postoperative thromboembolic complications. Data from
a larger population of patients with longer follow-up dura-
tion might resolve these limitations. The clinical implica-
tions of restored atrial contraction and its relationship with
MV operation type still remain unclear. This lack of clarity
merits a further study analyzing the clinical significance of
atrial contractility and the influences of various potential fac-
tors on atrial contractility.CONCLUSIONS
The addition of the maze procedure to MV surgery was
safe and effective in the treatment of AF associated with
MV disease. The clinical outcomes of the maze procedure
were excellent, regardless of type of MV surgery. Late AF
recurrence was mainly affected by patient age, electrocardio-
graphic characteristics of AF, and larger preoperative LA
size, not by type of MV surgery. Although LA contraction
was restored in most patients, LA contractility remained
less favorable in patients with MV replacement than in those
with MV repair.References
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J Am Coll Cardiol. 2001;37:1622-7.NTARYThe quest to identify predictors for success and failure after
the Cox-Maze procedure for the treatment of atrial fibrillationNiv Ad, MDIn this issue of the Journal, Dr Joon Bum Kim and
colleagues1 present their experience with more than 400
patients who underwent the modified Cox-Maze III proce-
dure combined with mitral valve surgery. This is a retrospec-
tive study designed to answer the interesting question ofwhether the type of mitral valve surgery performed has
any impact on the success rate of the surgical ablation.
This is a relatively large report to include 435 patients
(226 patients in the repair group). The main conclusion of
this study is that the success rate in ablation atrial fibrillation
was not affected by the type of the mitral valve surgery (re-
pair or replacement); however, left atrial transport was docu-
mented to be superior in the repair group. The predictors for
failure that were recognized in the study were the preopera-
tive age, fine atrial fibrillation wave pattern, and left atrial
size more than 6 cm preoperatively.
The authors of this article are to be congratulated for their
excellent results in a large series of patients. Nevertheless,rdiovascular Surgery c Volume 139, Number 1 117
